Many factors such as malignancy, thrombophilia, male gender, age, thrombus location, provoked versus unprovoked deep vein thrombosis (DVT), D-dimer elevation, and high body mass index have been studied as potential risk factors for venous thromboembolism (VTE) recurrence. 
were treated according to the American College of Chest Physicians (ACCP) clinical practice guidelines on antithrombotic and prevention of thrombosis. 2 Patients with DVT secondary to a transient risk factor were treated with 3 months of anticoagulation; patients with idiopathic DVT were treated with at least 3 months of anticoagulation; patients with DVT secondary to malignancy or who had thrombophilia were treated with long-term anticoagulation therapy.
2
Residual venous thrombosis was defined as the thrombus remaining the same or smaller using CUS after 3 months (or more) of anticoagulation. Recurrence was defined as the initial thrombus increasing in size or thrombus at a new site detected using CUS after 3 months or more. Complete resolution was defined as the resolution of the index thrombus using CUS after 3 months or more.
The subjects of our study were identified from our Vascular Diagnostic Laboratory patients' record. The patients who were included were registered with the Department of General Medicine, TTSH, Singapore between 2008 and 2013. Those patients included had a first episode of DVT, provoked or unprovoked, with or without pulmonary embolism, confirmed using CUS examination of the whole of the deep venous system of the lower limb, including the deep calf veins and subsequently after treatment with anticoagulation had RVO.
The technique which was used was similar to the Prandoni technique.
1 On the compressibility scan, a compressible vein was considered normal. If the vein could only be compressed partially, it suggested the presence of thrombus. On the longitudinal colored Doppler study, a normal biphasic pattern suggested that the vein had no thrombosis. If there was diminished phasicity, it suggested the presence of thrombus at that particular site. If there was a loss of phasicity, it suggested an occlusion, either by thrombosis or by a tumor occluding the vein, at a proximal site. VTE was diagnosed when the veins were not completely compressible, showing filling defects with pulsed and color Doppler interrogation. Computed tomography pulmonary angiography was done if pulmonary embolism (PE) was suspected at initial presentation. The presence of thrombophilia, malignancy, prolonged immobilization, recent trauma, recent surgeries, recent pregnancy, and drug history, in particular, oral contraceptive pills and hormone replacement therapy were recorded. These patients were followed up with the Department of General Medicine Vascular Clinic for a minimum of 3 months. All the patients received the standard management for DVT in our institution. Patients were treated with a minimum of 5 days with low-molecular-weight heparin, for example, enoxaparin (1 mg/kg) subcutaneous injection twice daily. Warfarin was also commenced on the day of diagnosis and heparin therapy was discontinued after 5 days or when the international normalized ratio was in the therapeutic range of 2 to 3. Warfarin therapy was continued in accordance with the latest ACCP guidelines.
Repeat ultrasonography was performed after 3 months of warfarin therapy, using the same ultrasound technique as illustrated above. Patients with RVO were included in our study.
The following patients were excluded from our study. Statistical analysis was performed using Stata/SE 13.1 (StataCorp LLC). Subjects were classified into those with and without RVO. Those with RVO were followed up for a minimum of 1 year to monitor for VTE recurrence. The incidence of recurrent VTE was then recorded and stratified for confounders, to determine if the presence of RVO increased the risk of VTE recurrence. Cox proportional hazards were used to assess the significance of potential risk factors on time to recurrence, and results were reported as hazard ratios with 95% confidence intervals. A p value <0.05 was considered statistically significant.
The study was approved by the National Healthcare Group DSRB, Singapore.
Results
A total of 50 patients from the Vascular Diagnostic Laboratory, TTSH, had a confirmed first-lifetime diagnosis of DVT with RVO between January 2008 and December 2013. Of the 50 patients, 7 were excluded from the study as they were admitted to other departments, 2 were excluded as they had a DVT of the upper limb, 1 was excluded as the DVT was located in the superficial mesenteric vein, 2 were excluded as they had IVC filters inserted, and 4 were excluded as they were lost to follow-up. The 34 patients who met the inclusion criteria were analyzed in our study. Their mean AE standard deviation (SD) age at onset was 66.9 AE 14.5 years. A total of 20 patients were females (58.8%), and 14 were males (41.2%). Overall, 30 patients were Chinese (88.2%), 2 patients were Malay (5.9%), and 2 were Indian (5.9%). Of the total index DVT cases, 21 (61.7%) were provoked while 13 (38.2%) were unprovoked. A total of 16 patients (47.1%) involved the common femoral vein or superficial femoral vein, 11 (32.4%) involved the common iliac vein, 4 (11.8%) involved the popliteal vein, and 3 (8.8%) involved the calf vein.
All patients received standard DVT treatment. The mean AE SD durations of oral anticoagulation therapy was 24.5 AE 3.7 months. The patients were followed up with the Department of General Medicine, Vascular Medicine Anticoagulation Clinic for a mean AE SD of 25.4 AE 2.4 months.
Bivariate analysis followed by multivariate analysis was performed to determine whether the various factors such as gender, race, veins involved, provoked or unprovoked DVT, the presence of malignancy or thrombophilia, treatment duration and follow-up duration increased the risk of recurrent VTE.
Among the 14 males included in the study, 3 (21.4%) had recurrent VTE while among the 20 females, 3 (15.0%) had recurrent VTE. With regards to race, 5 out of 30 Chinese (16.7%), 1 out of 2 Malays (50.0%), and 0 out of 2 Indians (0%) had recurrent VTE. With regards to thrombus location for index DVT event, 1 out of 11 patients with common iliac vein thrombus (9.8%), 4 out of 16 patients with superficial and common femoral vein thrombus (25.0%), 0 out of 4 patients with popliteal vein thrombus (0%), and 1 out of 3 patients with calf veins thrombosis (33.3%) developed recurrent VTE. The patient with an index calf vein DVT had a recurrence involving the common iliac vein. A possible reason for patients with common iliac vein DVT having significantly lower percentage of recurrence than patients with superficial/common femoral vein and calf vein DVT was the treatment duration (►Table 1). In this study, it was noted that patients with common iliac vein thrombus had the longest duration of treatment in months (mean: 29, range: 6-48), superficial femoral and common femoral veins (mean: 11.8, range: 3-36), popliteal vein (mean: 18.8, range: 3-27), calf vein (mean: 9, range: 3-18). Multivariate analysis showed that there was a significant association between thrombophilia and malignancy and the risk of recurrent VTE. Of the five patients who had thrombophilia at presentation, three (60%) had a recurrent VTE. Of the three patients who had malignancy at presentation, two (66.7%) had a recurrent VTE (►Table 2).
Discussion
There are many definitions of RVO. The extended DACUS study showed that RVOþ patients treated with 2 years of anticoagulation had higher VTE recurrence than the RVOÀ group despite the longer duration of anticoagulation therapy. 1 The DACUS and extended DACUS trials were the main determinants of significant differences in VTE recurrence between RVOþ and RVOÀ in this meta-analysis. 1 They also observed very low rate of VTE recurrence (1.3-1.5%) in RVOÀ group compared with our studies. Also, Carrier et al 1 published a meta-analysis that showed that RVO was mildly predictive of recurrent VTE when provoked and unprovoked DVT cases were analyzed together. 1 However, the association was absent when only unprovoked DVT cases were evaluated. 1 Tan et al performed a meta-analysis that found the modest risk of VTE recurrence in patients with RVO, but the association was heterogeneous and dependent on many variables. 1 Donadini et al in their meta-analysis identified RVO, age and male gender to be significant predictors of VTE recurrence. 1 There were significant heterogeneities of the many RVO-related studies, such as different RVO definitions, variable timing of repeat CUS to assess RVO, the inclusion of provoked and unprovoked VTEs, and the location of index DVT was not consistently reported in some articles.
1
Our study showed that the RVOþ patients had a VTE recurrence rate of 17.6%. One limitation of our study was we did not have the data on VTE recurrence rate in RVOÀ patients as they were excluded. We, however, have compared the VTE recurrence rate in RVOÀ patients in DACUS study and another study done in Korea. The DACUS study observed the very low rate of VTE recurrence in patients without RVO, and it was one of the main drivers of statistically significant increased VTE recurrence risk in RVOþ patients. 1 In DACUS study, the recurrence rate of VTE was 23.3 and 1.3% in RVOþ and RVOÀ group, respectively. 1 In a study conducted in Korea, the cumulative percentage of VTE recurrence in RVOþ and RVOÀ groups was approximately 10 and 5%, respectively, at 24 months, and RVO was concluded as a significant predictor of VTE recurrence in the study. 3 Having compared with the percentage of VTE recurrence in RVOÀ groups in DACUS study and the Korean study, we concluded that RVO is highly predictive of VTE recurrence in Singaporean population. As all of the RVOþ patients in our study developed recurrent DVT after the cessation of anticoagulation, it is advisable to give long-term anticoagulation for this group of patients. It is known that Asians have relatively low incidence and prevalence of VTE.
3 Inherited thrombophilia mutations such as Factor V Leiden, and prothrombin G20210A are not found in Chinese, Japanese, or Taiwanese. 3 These reflected the racial disparities in VTE. Clinical factors associated with VTE recurrence have also not been well studied in Asian populations. 3 In a study done in Korea, 303 patients with newly diagnosed VTE were followed up to evaluate the risk factors for recurrent VTE events. The study concluded that independent predictors for recurrent VTE were residual thrombosis and antiphospholipid syndrome. Extended anticoagulation was advocated in these groups. 3 In our study, the subjects were 34 Singaporeans consisted of 30 (88%) Chinese, 2 (6%) Indians, and 2 (6%) Malays. Our study showed that the presence of RVO was predictive of VTE recurrence in Singaporeans of which the majority was Chinese by ethnicity. More prospective studies should be done in the future to assess the predictors of VTE recurrence in the Asian population.
Other than VTE recurrence prediction, RVO at 3 months after anticoagulation for DVT was found to be associated with higher risk of postthrombotic syndrome (PTS), symptomatic arterial thrombotic events, and cancer. 4 These were not The 2009 AESOPUS study concluded that tailoring the duration of anticoagulation on the basis of ultrasonography findings of RVO reduces the rate of recurrent VTE in adults with proximal DVT.
7 For our study, there was no significant association between treatment duration ( 1 vs. > 1 year) and VTE recurrence (OR: 3.1, 95% CI: 0.5-19.8, p ¼ 0.2342). However, one of the main factors contributing to the lack of association could be probably small cohort size of RVT.
As repeat CUS at the end of anticoagulation to assess for RVO incurs the significant medical cost and our study is a retrospective cohort study with no direct comparison of VTE recurrence incidence in the RVOÀ patients, we are unable to make a recommendation about routine surveillance CUS to assess for RVO. More prospective randomized trials should be performed especially in Singaporean population to study the role of RVO in VTE recurrence prediction. The association between RVO and malignancy, arterial thrombosis, and PTS also warrants further research.
Conclusion
The presence of RVO after 3 months of anticoagulation is likely to increase the risk of VTE recurrence. Larger studies with RVO are needed to evaluate if there is increased the risk of VTE recurrence in the Asian population.
